The Moderna Covid-19 vaccine awaits administration at a vaccination clinic in Los Angeles, California on December 15, 2021.
Frederic J. Brown | AFP | Getty Images
Moderna on Tuesday said it expects to see between $8 billion and $15 billion in sales from its Covid, RSV, flu and other respiratory vaccines in 2027.
The biotech company said it sees a corresponding operating profit within the range of $4 billion to $9 billion. Those respiratory product estimates are supported by additional research investments of $6 billion to $8 billion “over the subsequent few years,” Moderna added.
The announcement got here ahead of Moderna’s Vaccine Day on Tuesday. On the annual event, the corporate presented updates on its vaccine portfolio to investors and analysts desirous to see how the corporate will navigate its post-pandemic boom.
Moderna said earlier this 12 months it expects $5 billion in mRNA Covid vaccine sales in 2023, a steep drop from the $18 billion the shot raked in last 12 months. The Cambridge, Massachusetts-based company’s Covid vaccine stays its only commercially available product.
Moderna’s highly anticipated flu vaccine didn’t meet the factors for early success in a late-stage clinical trial, the corporate said.
Moderna highlighted efforts to beef up its pipeline, saying it expects to launch six major vaccine products “in the subsequent few years.”
The brand new 2027 guidance “represents an upside to the low profitability expected this 12 months given the smaller” Covid market, Jefferies Analyst Michael Yee wrote in a Tuesday note.
But Yee said to expect investors to debate the guidance since it’s unclear “where seasonal viruses are going especially COVID for now.”
RSV vaccine
Moderna said its experimental RSV vaccine is among the many “big three” respiratory products that can contribute to the corporate’s lofty 2027 guidance.
The corporate expects to file for full approval of the shot for adults ages 60 and older this quarter. The “best case scenario” is getting a choice from the Food and Drug Administration around the top of this 12 months or early 2024, in accordance with Christine Shaw, Moderna’s portfolio head of respiratory vaccines.
Moderna is racing closely behind drugmakers Pfizer and GSK to launch the world’s first vaccine against the deadly virus, which infects the lungs and respiratory tract and typically causes mild, cold-like symptoms. Most individuals recuperate in per week or two, but RSV kills 6,000 to 10,000 seniors and a number of hundred children, younger than 5, annually.
Moderna’s RSV vaccine received Breakthrough Therapy Designation from the FDA in late January. That designation is meant to expedite the event and review of medication for serious or life-threatening conditions, and was based on positive topline data from Moderna’s phase three clinical trial on the vaccine.
Moderna’s vaccine was 83.7% effective in stopping RSV with two or more symptoms in people ages 60 and older, and 82.4% effective at stopping lower respiratory tract disease with three or more symptoms. No safety concerns were identified through the trial.
Notably, Shaw said, no cases of Guillain-Barre Syndrome were reported. Cases of the nervous system disorder have dogged shots from Pfizer and GSK, a key concern of the FDA advisors who really useful those vaccines.
Shaw noted that Moderna also has a “very energetic” pediatric program studying its RSV shot in children. She said the corporate recently initiated a pediatric study in children five months to 2 years old. The study evaluates the RSV shot in those children in addition to a latest combination vaccine that targets RSV and one other common respiratory virus called human metapneumovirus.